# LEGEND-2 (NCT03090659)

> LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03090659
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: Nanjing Legend Biotech Co.
- Conditions: Refractory or Relapsed Multiple Myeloma
- Interventions: LCAR-B38M CAR-T cell injection
- Enrollment: 100
- Primary outcome: Occurrence of treatment related adverse events as assessed by CTCAE v4.0

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 4
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=legend-2-nct03090659

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03090659", "email": "<work email>"}; the inbox owner confirms by the emailed link.